Clazosentan is under clinical development by Idorsia Pharmaceutical and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Clazosentan’s likelihood of approval (LoA) and phase transition for Cerebral Vasospasm took place on 22 Jan 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Clazosentan Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Clazosentan overview

Clazosentan Sodium (Pivlaz) is an anti cerebral vasospastic agent. It is formulated as solution for intravenous route of administration. Pivlaz is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH).

Idorsia Pharmaceutical overview

Idorsia Pharmaceutical (Idorsia) is a biopharmaceutical company that discovers, develops, and commercializes small molecules to treat the central nervous system and cardiovascular and immunological disorders. It is investigating daridorexant against insomnia; aprocitentan for the treatment of resistant hypertension; clazosentan to treat cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage; and L-lucerastat compound targeting fabry disease. The company is also evaluating drugs against suspected acute myocardial infarction, systemic lupus erythematosus, Binge eating disorder, and rare lysosomal storage disorders. It works in collaboration with Janssen Biotech to develop and commercialize Aprocitentan drug candidates. Idorsia is headquartered in Allschwil, Switzerland.

Quick View Clazosentan LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Clazosentan
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.